← Human Trials & Peer-Reviewed Studies
Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation.
Plain-language guide to PMID 26989846 (2016): open-label randomized controlled trial of Angiotensin II.
Key Facts
- PMID
- 26989846
- Journal
- Journal of clinical hypertension (Greenwich, Conn.)
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Kario K et al. (9 authors)
- DOI
- 10.1111/jch.12814
- Registered trial
- NCT01748253
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II in this randomized controlled trial publication.
It has long been thought that there is a close association between hypertension and atrial fibrillation (AF).
The present study was a multicentered, prospective, randomized, open-label clinical trial investigating the differences in the effect of treatment with telmisartan/amlodipine combination tablets on blood pressure (BP) levels and BP variability between morning and bedtime administration in hypertensive patients with paroxysmal AF, using ambulatory BP monitoring (ABPM) and home BP.
Who Took Part
PubMed tags the participants as both men and women.
How the Study Was Run
The design is described as randomized, open-label and multicenter.
Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.
Being open-label, the Angiotensin II study did not mask who received what.
Running at several centres spread the Angiotensin II study over different clinics and patient groups.
What Was Measured
The present study was a multicentered, prospective, randomized, open-label clinical trial investigating the differences in the effect of treatment with telmisartan/amlodipine combination tablets on blood pressure (BP) levels and BP variability between morning and bedtime administration in hypertensive patients with paroxysmal AF, using ambulatory BP monitoring (ABPM) and home BP.
Topics PubMed links to this paper include Amlodipine, Angiotensin II Type 1 Receptor Blockers, Atrial Fibrillation, Benzimidazoles, Benzoates, Blood Pressure and Blood Pressure Monitoring, Ambulatory.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Angiotensin II.
The publication is from 2016 (Journal of clinical hypertension (Greenwich, Conn.)), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.